公开(公告)号：US20230130403A1

公开(公告)日：2023-04-27

申请号：US18066883

申请日：2022-12-15

申请人： PRIOTHERA SAS ,  PRIOTHERA LIMITED

发明人： Christoph BUCHER ,  Simone DERTSCHNIG

IPC分类号： A61K31/145 ,  A61K38/13 ,  A61K31/519 ,  A61K31/7076 ,  A61K31/675 ,  A61K31/198 ,  A61K35/28 ,  A61P35/02 ,  A61K9/50 ,  A61K31/137 ,  A61K31/436 ,  A61K31/255 ,  A61P37/06 ,  A61K47/26 ,  A61K47/38 ,  A61K47/36 ,  A61K47/12 ,  A61K47/02 ,  A61K45/06 ,  A61K31/397 ,  A61K31/4245 ,  A61K31/426 ,  A61K31/404 ,  A61K31/4439 ,  A61K31/135

摘要： The present invention relates to S1P receptor modulators, preferably mocravimod, for use in treating patients suffering from a hematological malignancy, e.g., acute myeloid leukemia (AML), and who have undergone allogeneic hematopoietic stem cell transplantation (HSCT). The invention relates in particular to methods of treating AML in subjects undergoing HSCT, wherein said method comprises daily administering an efficient amount of S1P receptor modulator, preferably mocravimod, to said subject in need thereof, for at least 6 months, preferably at least 12 months.